Weight loss drugs aren’t just changing bodies—they’re flipping entire industries on their heads. With 1 in 8 adults now on GLP-1s and the market projected to explode to $150 billion by 2033, brands have a shot at reaching a new kind of consumer—one who is eating less, moving more, and rethinking everything from dinner to downtime. As appetite drives a shift in the way people shop, nimble marketers in every category have an opportunity to meet the moment. This panel will dive into the cultural ripple effect of weight loss drugs—and how creative leaders are helping to rebrand, reposition, and redefine what it means to be healthy in 2025.
Moderator:
Brian Robinson, Global Chief Strategy Officer, Head of Growth & GLP-1 Consultancy Lead, Havas Health Network
Panelists:
Christina Gutierrez-Williams, Director of Culinary R&D, Daily Harvest
Ugur Kucukcetin, Global Pharma Executive (formerly Novartis & Novo Nordisk)
Dr. Alexandra Sowa, MD, MA, Physician, Founder of SoWell and Author “The Ozempic Revolution”